0B68 Kelly, W. Kevin - Thomas Jefferson University - Thomas Jefferson University
Dr. Kelly

W. Kevin Kelly, DO

Contact Dr. Kelly

925 Chestnut Street
Suite 220A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Targeting Angiogenesis as a Promising Modality for the Treatment of Prostate Cancer
  2. An internet intervention for management of uncertainty during active surveillance for prostate cancer
  3. New therapies for castration-resistant prostate cancer: Efficacy and safety
  4. Epothilones in prostate cancer
  5. Genome-wide methylation analysis identifies involvement of TNF-α mediated cancer pathways in prostate cancer
  6. A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer
  7. The needs for men undergoing active surveillance (AS) for prostate cancer: Results of a focus group study
  8. Prostate cancer, comorbidity, and participation in randomized controlled trials of therapy
  9. Redefining hormone resistance in prostate cancer
  10. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials
  11. Anti-epidermal growth factor receptor monoclonal antibody cetuximab plus doxorubicin in the treatment of metastatic castration-resistant prostate cancer
  12. Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate Cancer
  13. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
  14. TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality
  15. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer
  16. Editorial Comment
  17. Epothilones: Tubulin p 06A9 olymerization as a novel target for prostate cancer therapy
  18. Epothilones: Tubulin polymerization as a novel target for prostate cancer therapy
  19. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: Results of cancer and leukemia group B 99811
  20. A phase II study of estramustine, docetaxel, and exisulind in patients with hormone-refractory prostate cancer: Results of cancer and leukemia group B trial 90004
0